Platelet deficiency, known as thrombocytopenia, can cause hemorrhage and is treated with
platelet transfusions. We developed a system for the production of platelet precursor cells …

The production of in vitro–derived platelets has great potential for transfusion medicine.
Here, we build on our experience in the forward programming (FoP) of human pluripotent …

Platelets, the chief effector of hemostasis, are small anucleate blood cells generated from
megakaryocytes (MKs), and the defects in platelet production or function lead to a variety of …

The production of megakaryocytes (MKs)—the precursors of blood platelets—from human
pluripotent stem cells (hPSCs) offers exciting clinical opportunities for transfusion medicine …

Platelet transfusions are critical for severe thrombocytopenia but depend on blood donors.
The shortage of donors and the potential of universal HLA-null platelet products have …

Megakaryocytes (MKs) are rare hematopoietic cells in the adult bone marrow and produce
platelets that are critical to vascular hemostasis and wound healing. Ex vivo generation of …

Background Platelets are small anucleate cells that circulate in the blood in a resting state
but can be activated by external cues. In case of need, platelets from blood donors can be …

The donor-dependent supply of platelets is frequently insufficient to meet transfusion needs.
To address this issue, we developed a clinically applicable strategy for the derivation of …

Abstract MRG-1 Human induced pluripotent stem cells (hiPSCs) are a promising source of
blood cells, including platelets, for transfusion. However, there remains a need for: 1) a …

Platelets, derived from megakaryocytes, are anucleate cytoplasmic discs that circulate in the
blood stream and play major roles in hemostasis, inflammation, and vascular biology …